AI-generated analysis. Always verify with the original filing.
At its Annual Meeting on March 11, 2026, Enanta Pharmaceuticals, Inc. stockholders re-elected Bruce L.A. Carter, Ph.D. and Jay R. Luly, Ph.D. as Class I directors, approved an amendment to the 2019 Equity Incentive Plan increasing shares reserved by 1,600,000, approved executive compensation on an advisory basis, and ratified PricewaterhouseCoopers LLP as independent auditors for fiscal 2026. The amended plan is filed as Exhibit 10.1.
Event Type
Disclosure
Mandatory
Variant
8-K
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As disclosed
Submission of Matters to a Vote of Security Holders. At the Annual Meeting held on March 11, 2026, Enanta’s stockholders voted on the following proposals, each
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 10.1 104 2019 Equity Incentive Plan (as amended March 2026) Cover Page Intera